> For the complete documentation index, see [llms.txt](https://www.brexatlas.org/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://www.brexatlas.org/bre-001/bre-025.md).
# BRE 025
## Therapeutic Electromagnetic Fields, Tumor Vascularity, and Breast Cancer Growth
**Clinical Cancer Name:** Breast Carcinoma
**Common Cancer Name:** Breast Cancer
## Source
Cameron, I. L., Markov, M. S., & Hardman, W. E. (2014).
*Optimization of a therapeutic electromagnetic field (EMF) to retard breast cancer tumor growth and vascularity.*
*Cancer Cell International, 14, 125.*
***
## BRS Score
**BRS:** 8.6 / 10\
**STEMD:** S9 / T8 / E9 / M9 / D8\
**External Evidence Level:** Moderate–High experimental in-vivo breast cancer EMF evidence
### Score Interpretation
BRE-025 receives a strong BRS because it provides experimental evidence that therapeutic EMF exposure reduced breast tumor growth and vascularity. Its value is especially high for translation because it shifts the focus from isolated cancer-cell behavior to tumor support systems, including angiogenesis and vascularity.
***
## Entry Summary
BRE-025 asks an important breast cancer question:
Can therapeutic electromagnetic fields slow breast tumor growth by disrupting the blood-vessel support system tumors need to survive?
Tumors need blood vessels to bring oxygen and nutrients. This process is called angiogenesis.
This study found that therapeutic EMF exposure reduced breast tumor growth, altered tumor vascularity, and increased necrotic regions in treated tumors.
In simple language:
Cancer tumors need a supply network. BRE-025 suggests electromagnetic fields may weaken that supply network.
***
## What BREXAtlas Found
BREXAtlas identifies BRE-025 as a tumor vascularity and anti-angiogenesis entry.
The primary mechanism chain is:
Therapeutic EMF exposure\
↓\
Tumor vascular disruption\
↓\
Reduced angiogenesis\
↓\
Increased necrotic tumor regions\
↓\
Reduced tumor growth
The secondary mechanism chain is:
Electromagnetic perturbation\
↓\
Oxidative stress signaling\
↓\
Tumor microenvironment destabilization\
↓\
Reduced tumor support capacity
This makes BRE-025 important because it expands breast cancer bioelectric oncology from cancer-cell stress to tumor-environment stress.
***
## Questions This BRE Helps Answer
What is angiogenesis?
Angiogenesis is the growth of new blood vessels.
Cancer tumors often use angiogenesis to feed themselves and keep growing.
What BREXAtlas found:\
BRE-025 supports that therapeutic EMF exposure may reduce breast tumor vascularity and contribute to anti-angiogenic tumor suppression.
What does tumor necrosis mean?
Necrosis means tissue death.
When tumor regions become necrotic, it may suggest that parts of the tumor are losing support, oxygen, or survival capacity.
What BREXAtlas found:\
BRE-025 reported increased necrotic regions in treated tumors, along with reduced tumor growth.
Is this the same as TTFields?
What BREXAtlas found:\
No.
BRE-025 studies therapeutic EMF exposure, not TTFields specifically.
It should not be generalized to all electric-field or electromagnetic-field systems. Its findings are tied to the specific exposure system studied.
***
## Study Classification
| Category | Classification |
| ----------------------------------------- | --------------------------------------------------------------- |
| Study Type | Experimental therapeutic EMF / tumor vascularity study |
| Tissue Category | Breast carcinoma |
| Common Cancer Name | Breast cancer |
| Models | Murine 16/C mammary adenocarcinoma; murine breast tumor systems |
| Exposure Type | Therapeutic electromagnetic field |
| Direct TTFields Evidence | No |
| Direct EMF Evidence | Yes |
| In-Vivo Tumor Evidence | Yes |
| Suitable for Mechanism Index | Yes |
| Suitable for Breast Cancer Index | Yes |
| Suitable for Tumor Microenvironment Index | Yes |
***
## Mechanisms
**MEC-033: Electromagnetic Anti-Angiogenesis**
Therapeutic EMF exposure may reduce tumor vascularity and angiogenesis.
**MEC-032: ROS-Electromagnetic Coupling**
Electromagnetic perturbation may interact with oxidative stress signaling.
**MEC-069: Tumor Vascular Suppression**
BRE-025 supports tumor vascular suppression as a possible electromagnetic response mechanism.
**MEC-070: Tumor Microenvironment Destabilization**
Reduced vascular support may destabilize the tumor microenvironment.
**MEC-071: Necrosis-Associated Tumor Suppression**
Increased necrotic regions may reflect weakened tumor support and reduced tumor growth.
***
## Discovery
**DISC-013: ROS and Electromagnetic Stress Integration**
BRE-025 supports the discovery that electromagnetic exposure may interact with oxidative stress and tumor stress pathways.
**DISC-016: Electromagnetic Anti-Angiogenic Tumor Suppression**
BREXAtlas identifies this entry as supporting a major tumor-level discovery:
Electromagnetic exposure may reduce tumor growth not only by stressing cancer cells directly, but also by weakening the tumor’s vascular support system.
***
## Connections to Other BRE Entries
### Connected to BRE-024
BRE-024 showed ELF-EMF exposure may trigger calcium disruption, ROS generation, mitochondrial stress, and altered viability in T47D breast cancer cells.
BRE-025 extends the electromagnetic stress pathway into tumor vascularity and growth suppression.
### Connected to BRE-023
BRE-023 focused on membrane potential and ion-channel signaling in breast cancer cells.
BRE-025 adds a tumor-environment layer: bioelectric and electromagnetic responses may affect not only cancer cells, but also tumor support systems.
### Connected to BRE-022
BRE-022 showed nanoparticle-assisted TTFields sensitization in breast cancer models.
BRE-025 provides a different amplification direction: altering the tumor microenvironment and vascular support.
### Connected to BRE-012
BRE-012 described cancer as a complex adaptive system.
BRE-025 fits that systems logic by showing that electromagnetic effects may involve the tumor microenvironment, angiogenesis, necrosis, oxidative stress, and tumor growth together.
***
## Research Gaps Identified
**RG-122: Exposure-System Specificity Gap**
More research is needed to determine whether the observed anti-angiogenic effects are specific to this therapeutic EMF system.
**RG-123: EMF Dose Optimization Gap**
Optimal frequency, field strength, exposure duration, and treatment schedule require further standardization.
**RG-124: Tumor Microenvironment Mechanism Gap**
More work is needed to determine exactly how EMF exposure alters tumor vascularity.
**RG-125: Normal Tissue Vascular Safety Gap**
More research is needed to determine how normal blood-vessel systems respond to similar exposure.
**RG-126: Breast Cancer Model Expansion Gap**
Findings should be compared across additional breast cancer models and human tumor systems.
***
## Scientific Caution
BRE-025 supports therapeutic electromagnetic anti-angiogenic effects under a specific exposure system. It should not be generalized to all EMF environments or exposure conditions.
***
## Why This Entry Matters
For researchers, BRE-025 is important because it moves electromagnetic oncology beyond direct cancer-cell effects and into tumor vascular support.
For patients and families, the simple idea is this:
Tumors need blood supply to grow. This study suggests electromagnetic fields may weaken that supply system in a breast cancer model.
This is not proof of a ready clinical treatment. It is experimental evidence that tumor vascularity may be part of the bioelectric oncology picture.
***
## Entry Conclusion
BRE-025 is a key tumor-level breast cancer entry in the BREXAtlas Encyclopedia.
BRE-023 showed breast cancer bioelectric instability.
BRE-024 showed electromagnetic stress through calcium, ROS, and mitochondria.
BRE-025 shows electromagnetic effects may also involve tumor vascularity, angiogenesis, necrosis, and growth suppression.
The central question emerging from this entry is:
Can therapeutic electromagnetic fields slow breast cancer growth by weakening the tumor’s vascular support system?
For BREXAtlas, BRE-025 is important because it connects bioelectric oncology to the tumor microenvironment.
---
# Agent Instructions
This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com.
## Querying This Documentation
If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.
Perform an HTTP GET request on the current page URL with the `ask` query parameter, and the optional `goal` query parameter:
```
GET https://www.brexatlas.org/bre-001/bre-025.md?ask=&goal=
```
`ask` is the immediate question: it should be specific, self-contained, and written in natural language.
`goal` is optional and describes the broader end goal you are ultimately trying to accomplish on behalf of the user. GitBook uses it to tailor the answer towards what is most useful for that goal.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.
Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.